Severe symptomatic aortic stenosis:medical therapy and transcatheter aortic valve implantation (TAVI)-a real-world retrospective cohort analysis of outcomes and cost-effectiveness using national data

Objectives: Determine the real-world difference\ud between 2 groups of patients with severe aortic\ud stenosis and similar baseline comorbidities: surgical\ud turn down (STD) patients, who were managed\ud medically prior to the availability of transcatheter aortic\ud valve implantation (TAVI) following formal surgical\ud outpatient assessment, and patients managed with a\ud TAVI implant.\ud Design: Retrospective cohort study from real-world\ud data.\ud Setting: Electronic patient letters were searched for\ud patients with a diagnosis of severe aortic stenosis and\ud a formal outpatient STD prior to the availability of TAVI\ud (1999–2009). The second group comprised the first 90\ud cases of TAVI in South Wales (2009 onwards). 2 years\ud prior to and 5 years following TAVI/STD were assessed.\ud Patient data were pseudoanonymised, using the Secure\ud Anonymized Information Linkage (SAIL) databank, and\ud extracted from Office National Statistics (ONS), PatientEpisode\ud Database for Wales (PEDW) and general\ud practitioner databases.\ud Population: 90 patients who had undergone TAVI in\ud South Wales, and 65 STD patients who were medically\ud managed.\ud Main outcome measures: Survival, hospital\ud admission frequency and length of stay, primary care\ud visits, and cost-effectiveness.\ud Results: TAVI patients were significantly older (81.8 vs\ud 79.2), more likely to be male (59.1% vs 49.3%),\ud baseline comorbidities were balanced. Mortality in TAVI\ud versus STD was 28% vs 70% at 1000 days follow-up.\ud There were significantly more hospital admissions per\ud year in the TAVI group prior to TAVI/STD (1.5 (IQR 1.0–\ud 2.4) vs 1.0 IQR (0.5–1.5)). Post TAVI/STD, the TAVI\ud group had significantly lower hospital admissions (0.3\ud (IQR 0.0–1.0) vs 1.2 (IQR 0.7–3.0)) and lengths of stay\ud (0.4 (IQR 0.0–13.8) vs 11.0 (IQR 2.5–28.5), p